1. Scrip
  2. >>R&D
  3. >>Clinical Trials

BMS Sees Zeposia As Safer Oral Option In Ulcerative Colitis

Efficacy Comparable To Gilead/Galapagos JAK Inhibitor Filgotinib

 
• By Mandy Jackson

Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response. 

Medical Concept: Ulcerative Colitis on Black Chalkboard. Medical Concept: Ulcerative Colitis - Black Chalkboard with Hand Drawn Text and Red Stethoscope. Top View. 3D Rendering.
Zeposia could be the first S1P receptor modulator approved for UC • Source: Shutterstock

Bristol Myers Squibb Company is building a case for its S1P receptor modulator Zeposia (ozanimod) as an effective, safer oral option for the treatment of moderate to severe ulcerative colitis based on new results from the Phase III TRUE NORTH clinical trial and as a cornerstone product in the company’s growing immunology portfolio and potential multi-drug gastrointestinal franchise.

BMS reported top-line results from TRUE NORTH in June and presented detailed data on 10 October during the United European...

More from Clinical Trials

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By Kevin Grogan

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold

 
• By Alaric DeArment

The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

More from R&D

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

Discontinuations For Viking’s Oral Obesity Drug VK2735 Scare Investors

 
• By Joseph Haas

Analysts lauded the 13-week weight-reduction rates Viking’s oral dual GLP-1/GIP agonist showed in Phase II, but the firm’s stock tumbled 42% due to high discontinuation rates.

Interest In PTC’s Sephience Launch Overshadows FDA’s Vatiquinone Rejection

 
• By Alaric DeArment

PTC said it got a complete response letter for the Friedreich’s ataxia drug, with the agency asking for an additional clinical trial.